Clinical trial packaging rarely gets the attention it deserves, but it’s one of the hidden engines that keeps studies running smoothly. A poorly designed kit, unclear labeling, or weak blinding strategy can slow down sites, confuse investigators, or trigger avoidable protocol deviations. Here are a few simple but critical tips for anyone planning clinical trial packaging—especially first-time sponsors or growing biotech teams.
1. Start Packaging Design Early—Much Earlier Than You Think
It’s common for packaging discussions to begin just before IMP release… and that’s usually too late. Packaging connects directly to protocol design, randomization, labeling requirements, and global regulatory submissions. The FDA and EMA both stress that investigational product labeling must align with study logistics from the beginning to avoid compliance gaps12.
A good rule of thumb:
Packaging planning should begin as soon as the draft protocol is available.
2. Keep Labels Clear, Legible, and Site-Friendly
Clinical sites move fast, and investigators juggle dozens of operational details. Labels must be:
- Easy to read
- Durable
- Free of clutter
- Compliant with regional requirements
- Compatible with blinding and randomization schemes
WHO GMP guidance emphasizes legibility, traceability, and durability as mandatory elements of investigational product labeling3. If a site coordinator has to squint to read your label, something’s wrong.
3. Design Kits With the End User in Mind
The “end user” isn’t the sponsor—it’s the clinical site.
Before locking in components, ask:
- Can a site open this kit quickly?
- Does the layout prevent use errors?
- Are ancillary supplies clearly separated?
- Does the packaging reduce chance of mix-ups?
Human-factor considerations are becoming more mainstream in clinical packaging, especially with complex modalities like injectables or self-administered products.
4. Don’t Underestimate Blinding and Randomization Complexity
Blinded trials depend on packaging that eliminates visual differences between active and placebo. That includes:
- Matching container color and fill volume
- Identical labeling except for randomization codes
- Using tamper-evident features
- Documenting blinding integrity in the TMF
Regulators expect sponsors to justify their blinding strategies, and packaging plays a central role in protecting trial validity1.
5. Build Temperature Control Into the Packaging Strategy
Even if you’re not shipping biologics, many small molecules and oral products still require controlled room-temperature conditions. Packaging must support:
- Stability data
- Temperature excursion limits
- Transit conditions
- Site storage capabilities
- Continuous chain-of-custody documentation
WHO GDP standards require validated packaging systems that protect IMP quality throughout distribution3.
6. Align Packaging Quantities With Your Enrollment Forecasts
Over-packaging wastes money, but under-packaging delays enrollment. Forecasting must consider:
- Screen failure rates
- Dropout rates
- Multi-country staggered starts
- Temperature-controlled supply constraints
Clinical supply bottlenecks—especially for biologics—have become a leading cause of study delays according to several global industry analyses4.
Conclusion
Clinical trial packaging sits at the intersection of science, logistics, and patient usability. When done well, it accelerates enrollment, supports blinding integrity, and protects product quality. When done poorly, it creates avoidable deviations, delays, and compliance risks. Starting early, designing with the site in mind, and following global regulatory expectations will help sponsors avoid the most common pitfalls.
References
Footnotes
- U.S. Food and Drug Administration (FDA). Investigational New Drug (IND) Requirements & Clinical Labeling Guidance. https://www.fda.gov ↩ ↩2
- European Medicines Agency (EMA). Investigational Medicinal Product Dossier (IMPD) and Labeling Requirements. https://www.ema.europa.eu ↩
- World Health Organization (WHO). Good Manufacturing Practices: Annex on Clinical Trial Materials & Labeling. https://www.who.int ↩ ↩2
- Deloitte Insights. Clinical Trial Supply Chain Outlook and Bottlenecks Report. ↩